Chakraborty, R
Muchtar, E
Kumar, S K
Buadi, F K
Dingli, D
Dispenzieri, A
Hayman, S R
Hogan, W J
Kapoor, P
Lacy, M Q
Leung, N
Warsame, R
Kourelis, T
Gonsalves, W
Gertz, M A
Article History
Received: 9 June 2017
Revised: 20 July 2017
Accepted: 2 August 2017
First Online: 14 August 2017
Competing interests
: MAG: research funding (Amgen, Celgene, Prothena, Ionis) and Honoraria (Celgene); AD: research funding (Prothena, Takeda, Celgene, Pfizer, Alnylam); PK: research support (Takeda, Celgene, Amgen); DD: consulting (Takeda, Janssen) and research support (Karyopharm Therapeutics); SKK: honoraria (Kesios Therapeutics, Noxxon Pharma, Skyline Diagnostics), consulting (Abbvie, Amgen, Bristol-Myers-Squibb, Janssen, Takeda) and research funding (Abbvie, Celgene, Janssen, Merck, Novartis, Sanofi, Takeda). The remaining authors declare no conflict of interest.